On Thursday, Brixmor Property Group Inc (NYSE:BRX)’s shares inclined 0.04% to $24.11.
Brixmor Property Group Inc (BRX) declared that its administration will present at the NAREIT REITWeek conference in New York, New York on Wednesday, June 10, 2015 from 2:45 PM ET to 3:15 PM ET.
Brixmor Property Group Inc. owns and operates various grocery-anchored community and neighborhood shopping centers in the United States. As of March 31, 2013, the company owned interests in 532 community and neighborhood shopping centers comprising 526 wholly owned community and neighborhood shopping centers; and 6 community and neighborhood shopping centers held through unmerged real estate joint ventures. Brixmor Property Group Inc. was formerly known as CENTRO SUPER RESIDUAL HOLDING 2 LLC.
Bruker Corporation (NASDAQ:BRKR)’s shares gained 0.68% to $20.59.
Bruker Corporation (BRKR) declared a major version 3.0 expansion of the proven Mycobacteria Library for research use only on the MALDI Biotyper microbial mass spectrometry system.
The new Mycobacteria Library 3.0 now comprises 149 different species for comprehensive species coverage, enabling significantly improved rapid and accurate identification of almost all described mycobacteria species. Intra-species diversity is covered by hundreds of analyzed strains. Twenty-four laboratories from nine countries from all over the world offered well-characterized clinical mycobacteria strains, concluding an already comprehensive set of isolates from strain collections. A recently published research study has shown that out of 1,045 mycobacteria samples, 94% could be identified on the species level with high confidence, and another 4.5% could be identified with lower confidence [1], using Mycobacteria Library 3.0.
Bruker Corporation, together with its auxiliaries, designs, manufactures, sells, and services proprietary life science and materials research systems, and associated products worldwide. It operates through two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies.
At the end of Thursday’s trade, Air Lease Corp (NYSE:AL)‘s shares dipped -3.28% to $37.19.
Air Lease Corp (AL) amended and extended its four-year unsecured revolving credit facility with JPMorgan Chase Bank, N.A., as administrative agent and the lenders named therein (as amended, the “Syndicated Unsecured Revolving Credit Facility”) whereby the Company extended the maturity date from May 5, 2018 to May 5, 2019 and raised the revolving commitments thereunder by an additional $350 million. The Syndicated Unsecured Revolving Credit Facility remains priced at LIBOR plus 125 basis points with a 25 basis point facility fee, subject to reductions based on improvements in the Company’s credit ratings.
Prior to the transaction, lenders held revolving commitments totaling $2.31 billion that matured on May 5, 2018. As a result of the transaction, lenders hold revolving commitments totaling $2.49 billion that mature on May 5, 2019, and lenders hold revolving commitments totaling $175 million that mature on May 5, 2018.
Air Lease Corporation engages in the purchase and leasing of commercial jet transport aircraft to airlines worldwide. The company also sells aircraft from its operating lease portfolio to third parties, counting other leasing companies, financial services companies, and airlines. In addition, it provides fleet administration services to investors and owners of aircraft portfolios.
Retrophin Inc (NASDAQ:RTRX), ended its Thursday’s trading session with 1.92% gain, and closed at $33.49.
Retrophin Inc (RTRX) declared the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RE-024, the Company’s novel investigational phosphopantothenate replacement therapy, for the treatment of pantothenate kinase-associated neurodegeneration (PKAN). PKAN is a rare and lethal autosomal recessive neurodegenerative disorder believed to affect about one to three persons per million worldwide, with no approved treatment presently accessible. Retrophin is presently enrolling healthy volunteers in its Phase 1 clinical trial evaluating the safety and tolerability of single oral doses of RE-024.
Fast Track designation is intended to aid the development of drugs to treat serious conditions with unmet medical needs, and expedite the review process with a aim of reaching patients earlier. A drug that receives Fast Track designation may be eligible for more frequent communication with the FDA to talk about development plans and clinical trial design, in addition to Accelerated Approval and Priority Review. The developing company may also be eligible for Rolling Review, which enables the submission of accomplished sections of its New Drug Application (NDA) for review by the FDA before the company submits a complete application.
Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases. Its product line comprises Cholbam, a cholic acid for the treatment of bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of peroxisomal disorders, such as Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea, or complications from reduced fat soluble vitamin absorption; Thiola, which is indicated for the prevention of cystine stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification, or who have adverse reactions to d-penicillamine; and Chenodal, a synthetic oral form of chenodeoxycholic acid for radiolucent stones in well-opacifying gallbladders.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
